<?xml version="1.0" encoding="UTF-8"?>
<p id="Par67">In patients with chronic spontaneous urticaria (CSU) unresponsive to 2nd generation H1-antihistamines, ongoing treatment with omalizumab should not be discontinued during the COVID-19 pandemic.</p>
